Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia

Blood

Volumn 111, Issue 3, 2008, Pages 1110-1116

  Visco, Carlo ^a   Ruggeri, Marco ^a   Evangelista, Maria Laura ^b   Stasi, Roberto ^b   Zanotti, Roberta ^c   Giaretta, Ilaria ^a   Ambrosetti, Achille ^c   Madeo, Domenico ^a   Pizzolo, Giovanni ^c   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b REGINA APOSTOLORUM HOSPITAL   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN; PREDNISONE; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; PRIORITY JOURNAL; PROGNOSIS; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

EID: 38949111420     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-09-111492     Document Type: Article

References (39)

1. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:230-239.
2. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25:80-97.
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
4. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
5. Kelton JG, Murphy WG, Lucarelli A, et al. A prospective comparison of four techniques for measuring platelet-associated IgG. Br J Haematol. 1989;71:97-105.
6. Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol. 1999;104:442-447.
7. Ebbe S, Wittels B, Dameshek W. Autoimmune thrombocytopenic purpura ("ITP" type) with chronic lymphocytic leukemia. Blood. 1962;19:23-37.
8. Dameshek W, Rubio F Jr., Mahoney JP, Reeves WH, Burgin LA. Treatment of idiopathic thrombocytopenic purpura (ITP) with prednisone. J Am Med Assoc. 1958;166:1805-1815.
9. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003;74:1-8.
10. Jones SE. Autoimmune disorders and malignant lymphoma. Cancer. 1973;31:1092-1098.
11. Cortes J, O'Brien S, Loscertales J, et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001;92:2016-2022.
12. Rubinstein DB, Longo DL. Peripheral destruction of platelets in chronic lymphocytic leukemia: recognition, prognosis and therapeutic implications. Am J Med. 1981;71:729-732.
13. Carey RW, McGinnis A, Jacobson BM, Carvalho A. Idiopathic thrombocytopenic purpura complicating chronic lymphocytic leukemia. Arch Intern Med. 1976;136:62-66.
14. Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood. 2002;100:2260-2262.
15. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma. 2003;44:1951-1955.
16. Ammatuna E, Marino C, Mitra ME, Calvaruso G, Iannitto E. Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab. Eur J Haematol. 2004;73:225-226.
17. Kaden BR, Rosse WF, Hauch TW. Immune thrombocytopenia in lymphoproliferative diseases. Blood. 53(4):545-551, 1979 Apr.
18. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
19. Visco C, Giaretta I, Ruggeri M, et al. Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia. Leukemia. 2007;21:1092-1093.
20. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
21. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HDDXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109:1401-1407.
22. The International Immunogenetics Information System. IMGT. http://imgt.cines.fr/. Accessed December 2006.
23. Centre for Protein Engineering. V-BASE. http://vbase.mrc-cpe.cam.ac.uk/. Accessed December 2006.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
26. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
27. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679-485.
28. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95:2786-2792.
29. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986;39:713-716.
30. Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol. 1987;67:235-239.
31. Barcellini W, Capalbo S, Agostinelli RM, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91:1689-1692.
32. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559-566.
33. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
34. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from literature analysis. Pediatr Blood Cancer. 2006;47:653-656.
35. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549-2554.
36. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
37. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879-2885.
38. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a key role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519-525.
39. Hervé M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest. 2005;115:1636-1643.